| | March 20166CIOReviewCopyright © 2016 CIOReview. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.CIOReviewMARCH - 25 - 2016Managing EditorJeevan GeorgeEditorial StaffAaron PierceAlex D'SouzaAva GarciaD. Tejaswi Joshua ParkerKyle SummersT:510.565.7559 VisualizersMatt RyderManjith FernandezBIOTECHNOLOGY SPECIALCIOReviewSalesStephen Thomas stephen.thomas@cioreview.comMailing AddressCIOReview44790 S. Grimmer Blvd Suite 202, Fremont, CA 94538T:510.402.1463, F:510-894-8405 MARCH -25 - 2016, Vol 05 SE 18 Published by CIOReview To subscribe to CIOReviewVisit www.cioreview.com Reinventing Quality Care The biotech industry is experiencing a significant traction in operating performance within an evolving regulatory and risk environment. The ongoing pricing and cost pressures, and adoption of new business models are affecting the entire value chain from R&D through treatment delivery. As a result, companies are aiming to enhance their operational aspects not only in the manufacturing aspect, but also in terms of finance, research and development, and safety. The agenda of "Do more with less" is compelling biotech companies to assess the value of their initiatives from a selling, general and administrative perspective. With the core focus to advance the patient-centric models, life sciences companies have an opportunity to seize patient engagement by supporting initiatives that are already in place. Companies use analytics and governance to achieve a proactive view of interventions over the course of the patient journey and determine factors such as discontinuation risk. This will also offer them a better view on how data is used and how patient engagement programs are instituted.Essentially, in a reform-driven switch to outcomes-focused, value-based payment and reimbursement systems, biotech organizations may continue to bear the brunt of public and private payers' efforts to control costs. In such a scenario, manufacturers are expected to experience the pressure to justify cost of their products and its comparative effectiveness against similar offerings.On that note, we present to you the special edition on biotechnology. We are featuring 20 Most Promising Biotech Technology Solution Providers, listing the best vendors and consultants that provide key technology solutions and services in this arena. We hope this information will help you optimize technology investments and deploy new capabilities.Jeevan GeorgeManaging Editoreditor@cioreview.comEditorial
< Page 5 | Page 7 >